Mediwound Ltd (NASDAQ:MDWD) Expected to Announce Quarterly Sales of $1.10 Million

Share on StockTwits

Equities analysts predict that Mediwound Ltd (NASDAQ:MDWD) will post sales of $1.10 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Mediwound’s earnings, with the highest sales estimate coming in at $1.20 million and the lowest estimate coming in at $1.00 million. Mediwound reported sales of $1.03 million during the same quarter last year, which indicates a positive year-over-year growth rate of 6.8%. The company is expected to report its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Mediwound will report full-year sales of $10.32 million for the current year, with estimates ranging from $7.80 million to $14.20 million. For the next fiscal year, analysts forecast that the company will post sales of $19.05 million, with estimates ranging from $13.80 million to $26.70 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Mediwound.

Mediwound (NASDAQ:MDWD) last released its quarterly earnings results on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.60 million. Mediwound had a negative net margin of 18.43% and a negative return on equity of 383.19%.

Several research firms recently weighed in on MDWD. Oppenheimer set a $22.00 price target on shares of Par Pacific and gave the company a “buy” rating in a report on Monday, March 25th. Zacks Investment Research cut shares of Farmland Partners from a “hold” rating to a “sell” rating in a report on Friday. Finally, ValuEngine cut shares of Virtu Financial from a “hold” rating to a “sell” rating in a report on Tuesday, June 18th.

Several hedge funds have recently made changes to their positions in MDWD. Millennium Management LLC boosted its holdings in shares of Mediwound by 33.2% during the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 17,048 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 16,840 shares in the last quarter. Oppenheimer & Co. Inc. boosted its holdings in shares of Mediwound by 6.5% during the 1st quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 2,000 shares in the last quarter. Menta Capital LLC boosted its holdings in shares of Mediwound by 200.2% during the 1st quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29,686 shares in the last quarter. Finally, Meitav Dash Investments Ltd. boosted its holdings in shares of Mediwound by 0.6% during the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock valued at $2,993,000 after buying an additional 3,536 shares in the last quarter. Hedge funds and other institutional investors own 30.78% of the company’s stock.

NASDAQ:MDWD traded down $0.02 during trading hours on Friday, hitting $3.20. The company had a trading volume of 32,947 shares, compared to its average volume of 63,955. The firm has a market cap of $87.52 million, a P/E ratio of -6.53 and a beta of 0.57. The company’s 50-day simple moving average is $3.67. Mediwound has a 52 week low of $3.00 and a 52 week high of $6.75. The company has a quick ratio of 3.79, a current ratio of 3.99 and a debt-to-equity ratio of 0.40.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.